Clinical Trial

Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Study acronym: STAR-01
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an single-arm, multicenter phase II study to evaluate the safety and efficacy of Sacituzumab Tirumotecan (sac-TMT) plus anlotinib in previously treated extensive-stage small cell lung cancer (ES-SCLC). The study is expected to enroll up to 33 eligible patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-24.
Trial Details
NCT Number NCT07501169
Lead Sponsor Sichuan University
Collaborators: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Enrollment 33 participants
Start Date 2026-04-01
Primary Completion 2027-08-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-13